Skip to Content

Fiasp Approval History

FDA Approved: Yes (First approved September 29, 2017)
Brand name: Fiasp
Generic name: insulin aspart
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Fiasp is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption.

Development History and FDA Approval Process for Fiasp

Sep 29, 2017Approval Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.